Aviceda Therapeutics is winding down operations after a Phase 2 failure for its geographic atrophy program, according to a source familiar with the decision. The company had planned to move an eye therapy into Phase 3 within the year despite the mid-stage setback. The shutdown highlights the downstream impact of Phase 2 readouts on smaller, single-asset ophthalmology biotechs, where a negative outcome can quickly eliminate the financing runway needed for late-stage preparations. It also underscores the risk profile of late-cycle translational strategies in retinal disease, where clinical endpoints and biomarker linkage can be decisive. For investors and partners, the development is a reminder that pipeline attrition can happen abruptly even when programs look positioned for scale-up, forcing quicker reassessment of asset valuation and go-forward plans.